Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies
John N. Allan(Cornell University), Jon Arnason(Beth Israel Deaconess Medical Center), Hesham Mohamed(Bristol-Myers Squibb (United States)), Matthew J. Matasar(Rutgers, The State University of New Jersey), Jan Walewski(The Maria Sklodowska-Curie National Research Institute of Oncology), Jennifer L. Crombie(Dana-Farber Cancer Institute), Max S. Topp(Universitätsklinikum Würzburg), Tae Min Kim(Seoul National University Hospital), Yuan Cheng(Taian City Central Hospital), Won-Seog Kim(Samsung Medical Center), Aafia Chaudhry(Regeneron (United States)), Dina M. Flink(Progenics Pharmaceuticals (United States)), Bertha Fearon Chalet(Regeneron (United States)), Srikanth Ambati(Regeneron (United States))
Cited by 6
Related Papers
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2017|736
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580